What's Going On With Aurinia Pharmaceuticals Stock Wednesday?

Aurinia Pharmaceuticals Inc AUPH shares are trading higher Wednesday after the company announced "promising results" from its AURORA Renal Biopsy Sub-Study.

The Details: The study showed that the addition of the company's oral medicine for the treatment of adult patients with active lupus nephritis, LUPKYNIS, on top of the current standard of care resulted in significantly earlier and greater reductions in proteinuria while maintaining stable renal function.

Repeat biopsies were collected from patients in both treatment arms over an 18-month period. The patients in the voclosporin treatment arm demonstrated histologic activity improvement with stable chronicity scores, which was similar to results seen in the active control arm.

The data "strengthens the totality of the evidence supporting the long-term efficacy and safety of LUPKYNIS and further differentiates the safety of this second-generation treatment from the legacy, first generation CNIs," said Greg Keenan, chief medical officer of Aurinia Pharmaceuticals.

The company said it will report more data at the Congress of Clinical Rheumatology meeting, which is set to kick off on May 4.

See Also: What's Going On With Johnson & Johnson Stock?

AUPH Price Action: Aurinia has a 52-week range of $4.07-$13.40.

The stock was up 3.05% at $10.46 at time of publication, according to Benzinga Pro.

Photo: fernando zhiminaicela from Pixabay.